Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel

INTRODUCTION: The implantation of the PRESERFLO™ MicroShunt (PMS) device has been shown to significantly lower increased intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). However, guidelines on best practice for patient selection and pre-/peri-/postoperative care manage...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OPHTHALMOLOGY AND THERAPY 2022-10, Vol.11 (5), p.1743-1766
Hauptverfasser: Khawaja, Anthony P, Stalmans, Ingeborg, Aptel, Florent, Barton, Keith, Beckers, Henny, Klink, Thomas, Marchini, Giorgio, de la Casa, Jose Martinez, Simonsen, Jan H, Toteberg-Harms, Marc, Vass, Clemens, Pinto, Luis Abegao
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1766
container_issue 5
container_start_page 1743
container_title OPHTHALMOLOGY AND THERAPY
container_volume 11
creator Khawaja, Anthony P
Stalmans, Ingeborg
Aptel, Florent
Barton, Keith
Beckers, Henny
Klink, Thomas
Marchini, Giorgio
de la Casa, Jose Martinez
Simonsen, Jan H
Toteberg-Harms, Marc
Vass, Clemens
Pinto, Luis Abegao
description INTRODUCTION: The implantation of the PRESERFLO™ MicroShunt (PMS) device has been shown to significantly lower increased intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). However, guidelines on best practice for patient selection and pre-/peri-/postoperative care management are lacking. The aim of this modified Delphi panel was to achieve expert consensus on the role of the PMS to treat patients with glaucoma in Europe. METHODS: Twelve European glaucoma surgeons experienced with the PMS procedure participated in a three-round modified Delphi panel. A targeted literature review and expert steering committee guided round 1 questionnaire development. Consensus was set at a pre-defined threshold of at least 70% of panellists selecting 'Strongly disagree'/'Disagree' or 'Strongly agree'/'Agree' for six-point Likert scale questions, or at least 70% selecting the same option for multiple-choice questions. Questions not reaching consensus were restated/revised for the next round, following guidance from free-text responses/scoping questions. RESULTS: Consensus was achieved for 60.3% (n = 38/63), 60.0% (n = 18/30), and 100.0% (n = 11/11) of Likert/multiple-choice questions in rounds 1, 2, and 3, respectively. There was agreement that the PMS procedure is effective at reducing IOP in patients with high-tension POAG (greater than 21 mmHg). Although surgical techniques may vary slightly, consensus was reached on several points, including the importance of posterior application of mitomycin C (MMC). Panellists agreed that the PMS postoperative follow-up appointment schedule is reasonably predictable and mostly characterised by fewer visits than with trabeculectomy, particularly in the early phase. Although panellists agreed that combined cataract/PMS surgery and the use of non-MMC wound-healing modulators/antifibrotics during the procedure are possible, further data are needed to determine efficacy. CONCLUSION: The expert consensus reached in this panel will help inform best practice guidelines in the treatment of patients with glaucoma in Europe. Panellists also highlighted key areas for future research to improve understanding of the PMS in the treatment algorithm of glaucoma.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_704561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_704561</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7045613</originalsourceid><addsrcrecordid>eNqVi0tuwjAURT2gUhFlD2-MROU4TiGdVRDKAFTEZ2xZyYviYuwotoEFdCUsjZUQ0S6gjO7R1Tkd0mVRGg_HjCfPpO_cN6U0YuMk5bxLTtm5xsbDxBqHxgUH1oCvEHYOwZZ3XK2zTbaeLb6uPxdYqryxmyoYD1M8qhxB_QbbBqU_YPu32aeWIbcH-Q4fsLSFKhUWra_rSsFKGtQv5KmU2mH_b3tkMMu2k_lwHzSGIxpRuFrmKBgVCaUiYilnYkR58hbFD8qv_5aFP_v4BtshXRY</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel</title><source>Open Access: DOAJ - Directory of Open Access Journals</source><source>Open Access: PubMed Central</source><source>Lirias (KU Leuven Association)</source><source>Springer_OA刊</source><source>Free E-Journal (出版社公開部分のみ)</source><creator>Khawaja, Anthony P ; Stalmans, Ingeborg ; Aptel, Florent ; Barton, Keith ; Beckers, Henny ; Klink, Thomas ; Marchini, Giorgio ; de la Casa, Jose Martinez ; Simonsen, Jan H ; Toteberg-Harms, Marc ; Vass, Clemens ; Pinto, Luis Abegao</creator><creatorcontrib>Khawaja, Anthony P ; Stalmans, Ingeborg ; Aptel, Florent ; Barton, Keith ; Beckers, Henny ; Klink, Thomas ; Marchini, Giorgio ; de la Casa, Jose Martinez ; Simonsen, Jan H ; Toteberg-Harms, Marc ; Vass, Clemens ; Pinto, Luis Abegao</creatorcontrib><description>INTRODUCTION: The implantation of the PRESERFLO™ MicroShunt (PMS) device has been shown to significantly lower increased intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). However, guidelines on best practice for patient selection and pre-/peri-/postoperative care management are lacking. The aim of this modified Delphi panel was to achieve expert consensus on the role of the PMS to treat patients with glaucoma in Europe. METHODS: Twelve European glaucoma surgeons experienced with the PMS procedure participated in a three-round modified Delphi panel. A targeted literature review and expert steering committee guided round 1 questionnaire development. Consensus was set at a pre-defined threshold of at least 70% of panellists selecting 'Strongly disagree'/'Disagree' or 'Strongly agree'/'Agree' for six-point Likert scale questions, or at least 70% selecting the same option for multiple-choice questions. Questions not reaching consensus were restated/revised for the next round, following guidance from free-text responses/scoping questions. RESULTS: Consensus was achieved for 60.3% (n = 38/63), 60.0% (n = 18/30), and 100.0% (n = 11/11) of Likert/multiple-choice questions in rounds 1, 2, and 3, respectively. There was agreement that the PMS procedure is effective at reducing IOP in patients with high-tension POAG (greater than 21 mmHg). Although surgical techniques may vary slightly, consensus was reached on several points, including the importance of posterior application of mitomycin C (MMC). Panellists agreed that the PMS postoperative follow-up appointment schedule is reasonably predictable and mostly characterised by fewer visits than with trabeculectomy, particularly in the early phase. Although panellists agreed that combined cataract/PMS surgery and the use of non-MMC wound-healing modulators/antifibrotics during the procedure are possible, further data are needed to determine efficacy. CONCLUSION: The expert consensus reached in this panel will help inform best practice guidelines in the treatment of patients with glaucoma in Europe. Panellists also highlighted key areas for future research to improve understanding of the PMS in the treatment algorithm of glaucoma.</description><identifier>ISSN: 2193-8245</identifier><language>eng</language><publisher>SPRINGER INT PUBL AG</publisher><ispartof>OPHTHALMOLOGY AND THERAPY, 2022-10, Vol.11 (5), p.1743-1766</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27860</link.rule.ids></links><search><creatorcontrib>Khawaja, Anthony P</creatorcontrib><creatorcontrib>Stalmans, Ingeborg</creatorcontrib><creatorcontrib>Aptel, Florent</creatorcontrib><creatorcontrib>Barton, Keith</creatorcontrib><creatorcontrib>Beckers, Henny</creatorcontrib><creatorcontrib>Klink, Thomas</creatorcontrib><creatorcontrib>Marchini, Giorgio</creatorcontrib><creatorcontrib>de la Casa, Jose Martinez</creatorcontrib><creatorcontrib>Simonsen, Jan H</creatorcontrib><creatorcontrib>Toteberg-Harms, Marc</creatorcontrib><creatorcontrib>Vass, Clemens</creatorcontrib><creatorcontrib>Pinto, Luis Abegao</creatorcontrib><title>Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel</title><title>OPHTHALMOLOGY AND THERAPY</title><description>INTRODUCTION: The implantation of the PRESERFLO™ MicroShunt (PMS) device has been shown to significantly lower increased intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). However, guidelines on best practice for patient selection and pre-/peri-/postoperative care management are lacking. The aim of this modified Delphi panel was to achieve expert consensus on the role of the PMS to treat patients with glaucoma in Europe. METHODS: Twelve European glaucoma surgeons experienced with the PMS procedure participated in a three-round modified Delphi panel. A targeted literature review and expert steering committee guided round 1 questionnaire development. Consensus was set at a pre-defined threshold of at least 70% of panellists selecting 'Strongly disagree'/'Disagree' or 'Strongly agree'/'Agree' for six-point Likert scale questions, or at least 70% selecting the same option for multiple-choice questions. Questions not reaching consensus were restated/revised for the next round, following guidance from free-text responses/scoping questions. RESULTS: Consensus was achieved for 60.3% (n = 38/63), 60.0% (n = 18/30), and 100.0% (n = 11/11) of Likert/multiple-choice questions in rounds 1, 2, and 3, respectively. There was agreement that the PMS procedure is effective at reducing IOP in patients with high-tension POAG (greater than 21 mmHg). Although surgical techniques may vary slightly, consensus was reached on several points, including the importance of posterior application of mitomycin C (MMC). Panellists agreed that the PMS postoperative follow-up appointment schedule is reasonably predictable and mostly characterised by fewer visits than with trabeculectomy, particularly in the early phase. Although panellists agreed that combined cataract/PMS surgery and the use of non-MMC wound-healing modulators/antifibrotics during the procedure are possible, further data are needed to determine efficacy. CONCLUSION: The expert consensus reached in this panel will help inform best practice guidelines in the treatment of patients with glaucoma in Europe. Panellists also highlighted key areas for future research to improve understanding of the PMS in the treatment algorithm of glaucoma.</description><issn>2193-8245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVi0tuwjAURT2gUhFlD2-MROU4TiGdVRDKAFTEZ2xZyYviYuwotoEFdCUsjZUQ0S6gjO7R1Tkd0mVRGg_HjCfPpO_cN6U0YuMk5bxLTtm5xsbDxBqHxgUH1oCvEHYOwZZ3XK2zTbaeLb6uPxdYqryxmyoYD1M8qhxB_QbbBqU_YPu32aeWIbcH-Q4fsLSFKhUWra_rSsFKGtQv5KmU2mH_b3tkMMu2k_lwHzSGIxpRuFrmKBgVCaUiYilnYkR58hbFD8qv_5aFP_v4BtshXRY</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Khawaja, Anthony P</creator><creator>Stalmans, Ingeborg</creator><creator>Aptel, Florent</creator><creator>Barton, Keith</creator><creator>Beckers, Henny</creator><creator>Klink, Thomas</creator><creator>Marchini, Giorgio</creator><creator>de la Casa, Jose Martinez</creator><creator>Simonsen, Jan H</creator><creator>Toteberg-Harms, Marc</creator><creator>Vass, Clemens</creator><creator>Pinto, Luis Abegao</creator><general>SPRINGER INT PUBL AG</general><scope>FZOIL</scope></search><sort><creationdate>202210</creationdate><title>Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel</title><author>Khawaja, Anthony P ; Stalmans, Ingeborg ; Aptel, Florent ; Barton, Keith ; Beckers, Henny ; Klink, Thomas ; Marchini, Giorgio ; de la Casa, Jose Martinez ; Simonsen, Jan H ; Toteberg-Harms, Marc ; Vass, Clemens ; Pinto, Luis Abegao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7045613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khawaja, Anthony P</creatorcontrib><creatorcontrib>Stalmans, Ingeborg</creatorcontrib><creatorcontrib>Aptel, Florent</creatorcontrib><creatorcontrib>Barton, Keith</creatorcontrib><creatorcontrib>Beckers, Henny</creatorcontrib><creatorcontrib>Klink, Thomas</creatorcontrib><creatorcontrib>Marchini, Giorgio</creatorcontrib><creatorcontrib>de la Casa, Jose Martinez</creatorcontrib><creatorcontrib>Simonsen, Jan H</creatorcontrib><creatorcontrib>Toteberg-Harms, Marc</creatorcontrib><creatorcontrib>Vass, Clemens</creatorcontrib><creatorcontrib>Pinto, Luis Abegao</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>OPHTHALMOLOGY AND THERAPY</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khawaja, Anthony P</au><au>Stalmans, Ingeborg</au><au>Aptel, Florent</au><au>Barton, Keith</au><au>Beckers, Henny</au><au>Klink, Thomas</au><au>Marchini, Giorgio</au><au>de la Casa, Jose Martinez</au><au>Simonsen, Jan H</au><au>Toteberg-Harms, Marc</au><au>Vass, Clemens</au><au>Pinto, Luis Abegao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel</atitle><jtitle>OPHTHALMOLOGY AND THERAPY</jtitle><date>2022-10</date><risdate>2022</risdate><volume>11</volume><issue>5</issue><spage>1743</spage><epage>1766</epage><pages>1743-1766</pages><issn>2193-8245</issn><abstract>INTRODUCTION: The implantation of the PRESERFLO™ MicroShunt (PMS) device has been shown to significantly lower increased intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). However, guidelines on best practice for patient selection and pre-/peri-/postoperative care management are lacking. The aim of this modified Delphi panel was to achieve expert consensus on the role of the PMS to treat patients with glaucoma in Europe. METHODS: Twelve European glaucoma surgeons experienced with the PMS procedure participated in a three-round modified Delphi panel. A targeted literature review and expert steering committee guided round 1 questionnaire development. Consensus was set at a pre-defined threshold of at least 70% of panellists selecting 'Strongly disagree'/'Disagree' or 'Strongly agree'/'Agree' for six-point Likert scale questions, or at least 70% selecting the same option for multiple-choice questions. Questions not reaching consensus were restated/revised for the next round, following guidance from free-text responses/scoping questions. RESULTS: Consensus was achieved for 60.3% (n = 38/63), 60.0% (n = 18/30), and 100.0% (n = 11/11) of Likert/multiple-choice questions in rounds 1, 2, and 3, respectively. There was agreement that the PMS procedure is effective at reducing IOP in patients with high-tension POAG (greater than 21 mmHg). Although surgical techniques may vary slightly, consensus was reached on several points, including the importance of posterior application of mitomycin C (MMC). Panellists agreed that the PMS postoperative follow-up appointment schedule is reasonably predictable and mostly characterised by fewer visits than with trabeculectomy, particularly in the early phase. Although panellists agreed that combined cataract/PMS surgery and the use of non-MMC wound-healing modulators/antifibrotics during the procedure are possible, further data are needed to determine efficacy. CONCLUSION: The expert consensus reached in this panel will help inform best practice guidelines in the treatment of patients with glaucoma in Europe. Panellists also highlighted key areas for future research to improve understanding of the PMS in the treatment algorithm of glaucoma.</abstract><pub>SPRINGER INT PUBL AG</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2193-8245
ispartof OPHTHALMOLOGY AND THERAPY, 2022-10, Vol.11 (5), p.1743-1766
issn 2193-8245
language eng
recordid cdi_kuleuven_dspace_20_500_12942_704561
source Open Access: DOAJ - Directory of Open Access Journals; Open Access: PubMed Central; Lirias (KU Leuven Association); Springer_OA刊; Free E-Journal (出版社公開部分のみ)
title Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A40%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expert%20Consensus%20on%20the%20Use%20of%20the%20PRESERFLO%E2%84%A2%20MicroShunt%20Device%20in%20the%20Treatment%20of%20Glaucoma:%20A%20Modified%20Delphi%20Panel&rft.jtitle=OPHTHALMOLOGY%20AND%20THERAPY&rft.au=Khawaja,%20Anthony%20P&rft.date=2022-10&rft.volume=11&rft.issue=5&rft.spage=1743&rft.epage=1766&rft.pages=1743-1766&rft.issn=2193-8245&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_704561%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true